Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics has partnered with the University of Pennsylvania to enroll patients in a Phase 1/2 clinical trial of their innovative CHM CDH17 CAR-T cell therapy for advanced gastrointestinal cancers. The trial aims to establish a recommended Phase 2 dose, assess safety, and measure the therapy’s response rate in treating colorectal, gastric, and neuroendocrine tumors. With positive preclinical results and multiple clinical stage programs underway, Chimeric Therapeutics is at the forefront of developing cell therapies for cancer treatment.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.